Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults

  1. Flavia Camponovo
  2. Joseph J Campo
  3. Timothy Q Le
  4. Amit Oberai
  5. Christopher Hung
  6. Jozelyn V Pablo
  7. Andy A Teng
  8. Xiaowu Liang
  9. B Kim Lee Sim
  10. Said Jongo
  11. Salim Abdulla
  12. Marcel Tanner
  13. Stephen L Hoffman
  14. Claudia Daubenberger
  15. Melissa A Penny  Is a corresponding author
  1. Swiss Tropical and Public Health Institute, Switzerland
  2. Antigen Discovery Inc, United States
  3. Sanaria Inc, United States
  4. Ifakara Health Institute, United Republic of Tanzania
  5. University of Basel, Switzerland

Abstract

Tanzanian adult male volunteers were immunized by direct venous inoculation with radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (PfSPZ Vaccine) and protective efficacy assessed by homologous controlled human malaria infection (CHMI). Serum immunoglobulin G (IgG) responses were analyzed longitudinally using a Pf protein microarray covering 91% of the proteome, providing first insights into naturally acquired and PfSPZ Vaccine-induced whole parasite antibody profiles in malaria pre-exposed Africans. Immunoreactivity was identified against 2,239 functionally diverse Pf proteins, showing a wide breadth of humoral response. Antibody-based immune 'fingerprints' in these individuals indicated a strong person-specific immune response at baseline, with little changes in the overall humoral immunoreactivity pattern measured after immunization. The moderate increase in immunogenicity following immunization and the extensive and variable breadth of humoral immune response observed in the volunteers at baseline suggest that pre-exposure reduces vaccine-induced antigen reactivity in unanticipated ways.

Data availability

All data analyzed during this study are included in the manuscript and supporting files, or sited accordingly when published elsewhere

Article and author information

Author details

  1. Flavia Camponovo

    Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    No competing interests declared.
  2. Joseph J Campo

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Joseph J Campo, is an employee of Antigen Discovery, Inc.
  3. Timothy Q Le

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Timothy Q Le, is an employee of Antigen Discovery, Inc.
  4. Amit Oberai

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Amit Oberai, is an employee of Antigen Discovery, Inc.
  5. Christopher Hung

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Christopher Hung, is an employee of Antigen Discovery, Inc.
  6. Jozelyn V Pablo

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Jozelyn V Pablo, is an employee of Antigen Discovery, Inc.
  7. Andy A Teng

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Andy A Teng, is an employee of Antigen Discovery, Inc.
  8. Xiaowu Liang

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Xiaowu Liang, is an employee of Antigen Discovery, Inc.
  9. B Kim Lee Sim

    Process Development and Manufacturing, Sanaria Inc, Rockville, United States
    Competing interests
    B Kim Lee Sim, This author is affiliated with Sanaria Inc. Sanaria manufactured PfSPZ Vaccine and PfSPZ Challenge.
  10. Said Jongo

    Interventions and Clinical Trials Unit, Bagamoyo Branch, Ifakara Health Institute, Dar es Salam, United Republic of Tanzania
    Competing interests
    No competing interests declared.
  11. Salim Abdulla

    Interventions and Clinical Trials Unit, Bagamoyo Branch, Ifakara Health Institute, Dar es Salam, United Republic of Tanzania
    Competing interests
    No competing interests declared.
  12. Marcel Tanner

    Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    No competing interests declared.
  13. Stephen L Hoffman

    Process Development and Manufacturing, Sanaria Inc, Rockville, United States
    Competing interests
    Stephen L Hoffman, This author is employed by Sanaria. Sanaria Inc. manufactured PfSPZ Vaccine and PfSPZ Challenge. Thus, all authors associated with Sanaria have potential conflicts of interest..
  14. Claudia Daubenberger

    University of Basel, Basel, Switzerland
    Competing interests
    No competing interests declared.
  15. Melissa A Penny

    Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    For correspondence
    melissa.penny@unibas.ch
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4972-593X

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_170702)

  • Melissa A Penny

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Urszula Krzych, Walter Reed Army Institute of Research, United States

Version history

  1. Received: October 26, 2019
  2. Accepted: July 10, 2020
  3. Accepted Manuscript published: July 14, 2020 (version 1)
  4. Version of Record published: July 28, 2020 (version 2)

Copyright

© 2020, Camponovo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,507
    views
  • 188
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Flavia Camponovo
  2. Joseph J Campo
  3. Timothy Q Le
  4. Amit Oberai
  5. Christopher Hung
  6. Jozelyn V Pablo
  7. Andy A Teng
  8. Xiaowu Liang
  9. B Kim Lee Sim
  10. Said Jongo
  11. Salim Abdulla
  12. Marcel Tanner
  13. Stephen L Hoffman
  14. Claudia Daubenberger
  15. Melissa A Penny
(2020)
Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults
eLife 9:e53080.
https://doi.org/10.7554/eLife.53080

Share this article

https://doi.org/10.7554/eLife.53080

Further reading

    1. Cancer Biology
    2. Epidemiology and Global Health
    Lijun Bian, Zhimin Ma ... Guangfu Jin
    Research Article

    Background:

    Age is the most important risk factor for cancer, but aging rates are heterogeneous across individuals. We explored a new measure of aging-Phenotypic Age (PhenoAge)-in the risk prediction of site-specific and overall cancer.

    Methods:

    Using Cox regression models, we examined the association of Phenotypic Age Acceleration (PhenoAgeAccel) with cancer incidence by genetic risk group among 374,463 participants from the UK Biobank. We generated PhenoAge using chronological age and nine biomarkers, PhenoAgeAccel after subtracting the effect of chronological age by regression residual, and an incidence-weighted overall cancer polygenic risk score (CPRS) based on 20 cancer site-specific polygenic risk scores (PRSs).

    Results:

    Compared with biologically younger participants, those older had a significantly higher risk of overall cancer, with hazard ratios (HRs) of 1.22 (95% confidence interval, 1.18–1.27) in men, and 1.26 (1.22–1.31) in women, respectively. A joint effect of genetic risk and PhenoAgeAccel was observed on overall cancer risk, with HRs of 2.29 (2.10–2.51) for men and 1.94 (1.78–2.11) for women with high genetic risk and older PhenoAge compared with those with low genetic risk and younger PhenoAge. PhenoAgeAccel was negatively associated with the number of healthy lifestyle factors (Beta = –1.01 in men, p<0.001; Beta = –0.98 in women, p<0.001).

    Conclusions:

    Within and across genetic risk groups, older PhenoAge was consistently related to an increased risk of incident cancer with adjustment for chronological age and the aging process could be retarded by adherence to a healthy lifestyle.

    Funding:

    This work was supported by the National Natural Science Foundation of China (82230110, 82125033, 82388102 to GJ; 82273714 to MZ); and the Excellent Youth Foundation of Jiangsu Province (BK20220100 to MZ).

    1. Epidemiology and Global Health
    Yuchen Zhang, Yitang Sun ... Kaixiong Ye
    Research Article

    Background:

    Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated with various chronic diseases and mortality, but results are conflicting. Few studies examined the role of omega-6/omega-3 ratio in mortality.

    Methods:

    We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants who had complete information on circulating PUFAs, 6461 died during follow-up, including 2794 from cancer and 1668 from cardiovascular disease (CVD). Associations were estimated by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.

    Results:

    Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs increased (all Ptrend <0.05). Comparing the highest to the lowest quintiles, individuals had 26% (95% CI, 15–38%) higher total mortality, 14% (95% CI, 0–31%) higher cancer mortality, and 31% (95% CI, 10–55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing stronger effects.

    Conclusions:

    Using a population-based cohort in UK Biobank, our study revealed a strong association between the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD mortality.

    Funding:

    Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under the award number R35GM143060 (KY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.